DiaMedica Therapeutics Inc. (DMAC) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Goldman Sachs raises humanoid robot forecast, sees auto role
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
November 13, 2023 4:28 PM ESTConference Call and Webcast November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time
Updated Amendment to Phase 2/3 ReMEDy2 AIS Protocol Aimed at Enhancing Patient Enrollment and Increasing Probability of Study Success, 30-Day FDA Review Period Passed Without Comment ReMEDy2 Initial Activation of Clinical Sites Expected in November and December $56 Million Cash with Runway to 2026MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a... More
